ArticleJournal of thoracic disease2026
Using actigraphy to evaluate physical activity in patients with pleural effusion: a pilot study.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Malignant pleural effusions (MPEs) are common in cancer patients and significantly impair physical activity. Although symptom relief is the primary treatment goal, the extent of activity limitation and the effectiveness of interventions remain unclear. We used actigraphy to assess the impact of thoracentesis on activity level. The primary objective was to evaluate the association between physical activity (via ActiGraph), quality of life [Short Form 6-Dimension index (SF-6D) utility score], and dyspnea (Borg scale) at weeks 1 and 2 following thoracentesis. Methods: We conducted a prospective, observational, single-center study in adults with symptomatic, moderate-to-large MPEs. Results: Participants wore actigraphy devices for a mean of 17.7 hours daily. Higher average steps in week 2 significantly correlated with higher week 2 SF-6D utility scores. Higher calorie expenditure in week 1 significantly correlated with better week 1 SF-6D utility scores. However, no actigraphy metrics significantly affected SF-6D utility score changes from week 1 to week 2. For Borg, higher average triaxial movement in week 2 was modestly associated with lower dyspnea in week 2. Greater week 1 increases (slopes) in calories, moderate-to-vigorous physical activity (MVPA), and triaxial movement significantly predicted larger Borg scale reduction from week 1 to week 2. Conclusions: These findings suggest that improvement in SF-6D utility scores is tied to average activity levels (calories in week 1, steps in week 2), whereas dyspnea improvement by Borg scale over time is more strongly related to early gains in week 1 activity. Triaxial movement was also associated with less dyspnea in week 2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.